These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3048049)

  • 1. Noradrenergic and serotonergic receptor system function in panic disorder and depression.
    Heninger GR; Charney DS; Price LH
    Acta Psychiatr Scand Suppl; 1988; 341():138-50. PubMed ID: 3048049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comorbidity of panic disorder and major depressive disorder: effects on platelet alpha 2 adrenergic receptors.
    Grunhaus LJ; Cameron O; Pande AC; Haskett RF; Hollingsworth PJ; Smith CB
    Acta Psychiatr Scand; 1990 Mar; 81(3):216-9. PubMed ID: 2160772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral indications for serotonin receptor hypersensitivity in panic disorder.
    Kahn RS; Wetzler S; van Praag HM; Asnis GM; Strauman T
    Psychiatry Res; 1988 Jul; 25(1):101-4. PubMed ID: 3217461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenergic status in anxiety disorders: platelet alpha 2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects.
    Cameron OG; Smith CB; Lee MA; Hollingsworth PJ; Hill EM; Curtis GC
    Biol Psychiatry; 1990 Jul; 28(1):3-20. PubMed ID: 2165422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cortisol response to clonidine in panic disorder: comparison with depressed patients and normal controls.
    Stein MB; Uhde TW
    Biol Psychiatry; 1988 Jul; 24(3):322-30. PubMed ID: 2840978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder.
    Charney DS; Heninger GR; Breier A
    Arch Gen Psychiatry; 1984 Aug; 41(8):751-63. PubMed ID: 6742977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panic disorder: a presynaptic serotonin defect?
    Kahn RS; van Praag HM
    Psychiatry Res; 1990 Feb; 31(2):209-10. PubMed ID: 2326399
    [No Abstract]   [Full Text] [Related]  

  • 8. Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder.
    Charney DS; Heninger GR
    Arch Gen Psychiatry; 1986 Nov; 43(11):1042-54. PubMed ID: 3021083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder.
    Abelson JL; Glitz D; Cameron OG; Lee MA; Bronzo M; Curtis GC
    Arch Gen Psychiatry; 1991 Feb; 48(2):157-62. PubMed ID: 1989571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholinergic-monoamine systems, depression, and panic.
    Dilsaver SC
    Biol Psychiatry; 1986 May; 21(5-6):571-3. PubMed ID: 3697449
    [No Abstract]   [Full Text] [Related]  

  • 11. Altered central alpha 2-adrenoceptor sensitivity in panic disorder.
    Nutt DJ
    Arch Gen Psychiatry; 1989 Feb; 46(2):165-9. PubMed ID: 2536539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blunted growth hormone response to clonidine in panic disorder patients.
    Uhde TW; Vittone BJ; Siever LJ; Kaye WH; Post RM
    Biol Psychiatry; 1986 Sep; 21(11):1081-5. PubMed ID: 3741921
    [No Abstract]   [Full Text] [Related]  

  • 13. Brain neurotransmission in panic disorder.
    Eriksson E
    Acta Psychiatr Scand Suppl; 1987; 335():31-7. PubMed ID: 2890266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients.
    Charney DS; Woods SW; Krystal JH; Nagy LM; Heninger GR
    Acta Psychiatr Scand; 1992 Oct; 86(4):273-82. PubMed ID: 1333719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline.
    Den Boer JA; Westenberg HG
    Int Clin Psychopharmacol; 1988 Jan; 3(1):59-74. PubMed ID: 2833543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder.
    Kahn RS; Asnis GM; Wetzler S; van Praag HM
    Psychopharmacology (Berl); 1988; 96(3):360-4. PubMed ID: 2906153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological alterations in the primary affective disorders and other tricyclic-responsive disorders.
    Siever LJ; Uhde TW; Insel TR; Kaye WH; Jimerson DC; Lake CR; Kafka M; Targum S; Murphy DL
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(1):15-24. PubMed ID: 2986198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet binding studies in panic disorder.
    Nutt DJ; Fraser S
    J Affect Disord; 1987; 12(1):7-11. PubMed ID: 3033042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs.
    Goodman WK; Charney DS
    J Clin Psychiatry; 1985 Oct; 46(10 Pt 2):6-24. PubMed ID: 3900056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normal urinary free cortisol and plasma MHPG in panic disorder: clinical and theoretical implications.
    Uhde TW; Joffe RT; Jimerson DC; Post RM
    Biol Psychiatry; 1988 Mar; 23(6):575-85. PubMed ID: 2833321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.